All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Does the improvement in RFS after FLAG-IDA + GO lead to more severe toxicities in CBF AML?

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal were delighted to speak to Gautam M. Borthakur, MD Anderson Cancer Center, Houston, US. We asked: Does the improvement in relapse-free survival after FLAG-IDA + gemtuzumab ozogamicin (GO) come at the cost of more severe toxicities in patients with core binding factor acute myeloid leukemia (CBF AML)?

Gautam Borthakur discusses the best regimens for the treatment of CBF AML, he explains FLAG-IDA based regimen gives a good patient outcome and he questions the associated toxicities that come from the addition of GO to the regimen. He then explains the FLAG-IDA + GO has proven efficacious such as better patient responses, including higher rates of relapse-free survival and MRD-negativity.

Does the improvement in RFS after FLAG-IDA + GO lead to more severe toxicities in CBF AML?